Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Medical Policy · PA · Oncology, Hematology, Internal MedicineMedium impact

08.00.75q, Erythropoiesis-Stimulating Agents (ESAs)

Act
by Nov 17, 2025
Effective date
Nov 17, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross updated ESA policy 08.00.75q to 08.00.75r effective 11/17/2025, revising coverage criteria for Myelodysplastic Syndrome and Cancer-Related Anemia based on FDA labeling and NCCN guidelines. Seven new ICD-10 diagnosis codes were added to expand eligible patient populations, including acute panmyelosis with myelofibrosis variants, myelodysplastic disease, chronic myeloproliferative disease, osteomyelofibrosis, and anemia in neoplastic disease.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Nov 17, 2025 · 4 steps
01Billing team must update coding systems to recognize the seven newly added ICD-10 diagnosis codes (C94.40, C94.41, C94.42, C94.6, D47.1, D47.4, D63.0, D75.81) as eligible for ESA coverage under policy 08.00.75r.
02Review current ESA claims for patients with these diagnoses to ensure prior authorization aligns with revised Myelodysplastic Syndrome and Cancer-Related Anemia criteria (serum erythropoietin ≤500 mU/mL, lower-risk disease confirmation, documentation of failed prior therapies where applicable).
03Remove outdated policy 08.00.75q from all reference materials and billing software.
04Providers should document all required criteria before treatment initiation, including hemoglobin <10 g/dL, planned chemotherapy duration, and palliative vs. curative treatment intent.
If missed: Failure to apply new criteria may result in claim denials or retroactive recoupment.

Codes mentioned

J0881J0882J0885J0887J0888Q4081Q5105Q5106C94.40C94.41C94.42C94.6D47.1D47.4D63.0D75.81

Original notice

08.00.75q, Erythropoiesis-Stimulating Agents (ESAs)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.011i, Erythropoiesis Stimulating Agents (ESAs)MediumEffective Jun 29, 2026 · Medical Policy08.00.75r, Erythropoiesis-Stimulating Agents (ESAs)MediumEffective Jun 15, 2026 · Medical PolicyMA08.110d, Luspatercept–aamt (Reblozyl®)MediumEffective Jan 17, 2025 · PharmacyMA08.110d, Luspatercept–aamt (Reblozyl®)HighEffective Jan 17, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesOncologyHematologyInternal MedicineCode J0881Code J0882Code J0885Code J0887Code J0888Code Q4081Code Q5105Code Q5106Code C94.40Code C94.41Code C94.42Code C94.6Code D47.1Code D47.4Code D63.0Code D75.81

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account